Biodexa Reports Serenta Trial Two-Thirds Enrolled, MTX240 Preparations Advance
at www.tipranks.com (Mon, 9-Nov 8:57 AM)
Biodexa reaches 100-patient milestone in Serenta Phase 3 FAP trial as futility analysis timing moves up
Market Chameleon (Wed, 14-Oct 10:26 AM)
